# A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA

> **NCT05601232** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Stella Pharma Corporation** · enrollment: 10 (estimated)

## Conditions studied

- Unresectable Angiosarcoma

## Interventions

- **RADIATION:** BNCT

## Key facts

- **NCT ID:** NCT05601232
- **Lead sponsor:** Stella Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2024-11-30
- **Final completion:** 2025-08-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05601232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05601232, "A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05601232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*